Select your country

Websites worldwide

Select a country to go to the website of the respective STADA sales company.

Belarus (1)

Belgium (1)

Bosnia-Herzegovina (1)

Bulgaria (1)

Croatia (1)

Denmark (1)

Hungary (1)

Italy (1)

Montenegro (1)

Portugal (1)

Romania (1)

Saudi Arabia (1)

Serbia (1)

Slovenia (1)

Switzerland (1)

The Phillippines (1)

United Arab Emirates (1)

Innovating to meet patient needs

STADA’s Specialty Pharmaceuticals segment delivers innovative, competitive medicines used to improve the lives and clinical outcomes of patients worldwide who live with chronic, complex or rare conditions.

Specialty pharmaceuticals typically have complex characteristics in terms of how they are manufactured, prescribed, distributed and administered and may include novel formulations and combinations, as well as new uses that add value to known active ingredients. Specialty medicines are integral to STADA’s purpose of Caring for People’s Health as they can address unmet medical needs and relieve financial pressures across healthcare systems.

How our Specialty Care is expanding access to life-altering therapies


Patients using device-aided Parkinson‘s therapy


Medicine approved in EU for rare kidney disease


Countries in Europe that offer access to high-quality biosimilars


Years of experience in biosimilars

Pharmacists in a laboratory

Our Specialty Pharmaceuticals portfolio consists of a diverse set of biosimilars as well as innovative products within complex therapeutic areas.

By continuously expanding our Specialty pipeline of medicines, growing our expertise and developing trusted partnerships, we continue to strengthen the performance of our Specialty Pharmaceuticals business.

What therapeutic areas are we focusing on?

We prioritize partnerships that help us in Caring for People’s Health as a Trusted Partner.  We currently offer high-quality medicines within the following therapeutic areas:

Bone Health

Bone Health

Teriparatide (biosimilar) – osteoporosis.




Adalimumab (biosimilar) – autoimmune diseases.



Epoetin zeta (biosimilar) – for symptomatic anemia associated with chronic renal failure.
Innovative targeted-release formulation of budesonide used to treat primary immunoglobulin A nephropathy (IgAN).



Device-driven combination of levodopa, carbidopa and entacapone – late-stage Parkinson’s.



Pegfilgrastim (biosimilar) – cancer patients with neutropenia. Bevacizumab (biosimilar) – cancers.



Ranibizumab (biosimilar) – ophthalmologic conditions.

"STADA‘s growing Specialty Pharmaceuticals business is committed to becoming the partner of choice for payers, physicians and patients by ensuring people living with chronic conditions have access to life-altering, high-quality and affordable treatments."


Executive Vice President Global Specialty Pharmaceuticals